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Abstract
Advanced glycation end products (AGEs) are produced 
through the non enzymatic glycation and oxidation of 
proteins, lipids and nucleic acids. Enhanced formation 
of AGEs occurs particularly in conditions associated with 
hyperglycaemia such as diabetes mellitus (DM). AGEs 
are believed to have a key role in the development and 
progression of cardiovascular disease in patients with 
DM through the modification of the structure, function 
and mechanical properties of tissues through crosslink-
ing intracellular as well as extracellular matrix proteins 
and through modulating cellular processes through 
binding to cell surface receptors [receptor for AGEs 
(RAGE)]. A number of studies have shown a correlation 
between serum AGE levels and the development and 
severity of heart failure (HF). Moreover, some studies 
have suggested that therapies targeted against AGEs 
may have therapeutic potential in patients with HF. The 
purpose of this review is to discuss the role of AGEs in 
cardiovascular disease and in particular in heart failure, 
focussing on both cellular mechanisms of action as well 
as highlighting how targeting AGEs may represent a 
novel therapeutic strategy in the treatment of HF.
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INTRODUCTION
Advanced glycation end products (AGEs) are a heter-
ogenous group of  molecules that are generated through 
non-enzymatic glycation and oxidation of  proteins, 
lipids and nucleic acids[1]. They alter tissue function and 
mechanical properties through crosslinking intracellular 
as well as extracellular matrix proteins[2-6] and through 
binding to their cell surface receptor, receptor for AGEs 
(RAGE), they are capable of  modulating multiple cellu-
lar processes[7-9]. Enhanced formation and accumulation 
of  AGEs has been reported to occur in conditions such 
as diabetes mellitus (DM) as well as in natural aging, re-
nal failure and chronic inflammation[10-12]. 
In vivo detectable AGEs include three main groups: 
(1) Fluorescent cross-linking AGEs such as pentosidine 
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and crossline[13]; (2) Non-fluorescent cross-linking AGEs 
such as imidazolium dilysine cross-links named either 
glyoxal lysine dimer or methylglyoxal lysine dimer result 
from reactions taking place between glyoxal derivatives 
and lysine residues[14] ; (3) Non-cross-linking AGEs such 
as N-carboxymethyllysine (CML)[15].
In patients with diabetes, cardiovascular complica-
tions are the principal cause of  morbidity and mortality 
and account for up to 65% of  diabetic fatalities[16]. It has 
been reported that 33% of  diabetic patients on insulin 
therapy will have died from cardiovascular disease by the 
age of  50 years[17]. It is thought that AGEs have a central 
role in the pathophysiological processes that lead to the 
development of  such cardiovascular complications ob-
served in diabetes. This review highlights how AGEs are 
formed, summarises the evidence for the role of  AGEs 
in the development of  cardiovascular complications in 
diabetic patients, as well as their underlying mechanisms 
of  action and finally we review the potential of  anti-
AGE therapies for their use in clinical practice.      
MAILLARD REACTION AND AGE 
SYNTHESIS
AGE are a spectrum of  heterogeneous compounds that 
are derived from proteins, lipids and nucleic acids that 
are glycated or oxidized non-enzymatically in a process 
termed the “Maillard reaction”[18]. D-glucose plays a pri-
mary role in glycation of  proteins in vivo due to its high 
concentration in human plasma[19]. The Maillard reac-
tion starts as a reaction between the carbonyl group of  
a reducing sugar such as glucose and the amino acid of  
proteins, lipids or nucleic acids leading to the production 
of  an unstable compound known as a “Schiff  base”. 
This step is reversible and usually takes a few hours to 
occur. Over weeks the Schiff  base turns into a more 
stable compound called the “Amadori” product through 
various molecular rearrangements. Over months and 
years, the Amadori products undergo further structural 
changes through a series of  reactions such as oxidation, 
dehydration and degradation to finally yield highly stable 
AGE compounds[20,21] (Figure 1).  
Highly reactive dicarbonyl compounds are generated 
during the conversion of  Amadori products to AGEs. 
Methylglyoxal and 3-deoxyglucosone are the best known 
AGE dicarbonyl precursors[22-24]. In vivo, CML is the most 
abundant form of  AGEs and is characterized by its 
highly antigenic nature[25,26].
It has been reported that non-enzymatic glycation 
of  proteins and formation of  AGEs affects the pro-
tein physiological functions and is capable of  inducing 
enzyme inactivation[27]. The influence of  such modifica-
tions on protein structure has been far less investigated. 
Recently, using nuclear magnetic resonance (NMR), 
Howard et al[28] have showed that glycation of  a model 
helical peptide from human serum albumin (HSA) by 
glucose caused distortion of  the helical structure of  the 
protein at the point of  glycation. Another protein struc-
tural study for the changes induced by non-enzymatic 
glycation in the secondary and tertiary protein structure 
of  HSA showed that the in general protein structure 
was unaltered. Instead the change was only limited to 
local regions after glycation. This was revealed using 
fluorescence-dependant methods[29].
AGES AND CARDIOVASCULAR DISEASE
AGEs are produced normally in the body and they accu-
mulate by age and are considered not only as biomarkers 
of  senescence but they correlate inversely with left ven-
tricular ejection fraction (EF) and can predict the outcome 
of  cardiac surgery in elderly patients. A direct linear corre-
lation between CML levels in the pericardial fluid and the 
age of  the patients was shown where mean CML level of  
260.8 ± 19.7 ng/mL was detected in patients with mean 
age 52.2 ± 1.3 years, mean CML level of  293.4 ± 18.8 ng/
mL was identified in patients with mean age 65.8 ± 0.6 
years and mean CML level of  357.0 ± 28.3 ng/mL was 
recorded at mean age 75.1 ± 0.6 years[30]. 
In addition, AGEs accumulate at a much higher rate 
in diabetics than in normal population. AGEs serum 
levels are much higher in diabetic patients when com-
pared to normal non diabetic population. AGE serum 
levels have been reported in a number of  clinical studies 
involving diabetic patients compared to healthy individu-
als. AGE levels were recorded as 7.4 U/mL in diabetic 
patients vs 4.2 U/mL in normal population, whereas 
CML levels reached 15.6 U/mL in diabetics vs 8.6 U/mL 
in nondiabetics. Serum AGEs were found to be signifi-
cantly elevated in diabetic patients with coronary heart 
disease (CHD) (8.1 U/mL) vs diabetics without CHD (7.1 
U/mL)[31]. In another study concerned with AGE tissue 
levels and the severity of  diabetic nephropathy, the aver-
age AGE content in arterial wall collagen of  diabetics 
was significantly higher than that of  samples obtained 
from nondiabetic patients (14.5 ± 5.2 U/mg vs 3.6 ± 1.5 
AGE U/mg). Furthermore, it was revealed that AGE 
content in renal tissues obtained from diabetic patients 
with end-stage renal disease is as twice as AGE content 
in tissue of  diabetic patients without renal disease (21.3 
± 2.8 U/mg vs 11.5 ± 1.9 AGE U/mg)[32]. Serum levels 
of  pentosidine were found to be significantly higher in 
patients with diabetes than in nondiabetic normal con-
trols (64.4 ± 21.0 μg/L vs 22.8 ± 7.0 μg/L). Moreover, 
serum pentosidine levels were significantly higher in dia-
betic patients with cardiovascular disease than in those 
without (72.3 ± 23.7 μg/L vs 62.3 ± 19.8 μg/L) and they 
were found to correlate with increased arterial wall stiff-
ness in diabetic patients[33].
AGES AND CARDIOVASCULAR 
COMPLICATIONS OF DIABETES
As mentioned above, several studies have shown a posi-
tive association between serum and tissue AGEs and 
macro and microvascular complications of  diabetes[31,34-39]. 
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The following sections overview how serum AGE levels 
correlate with the development and the progression of  
several cardiovascular complications of  diabetes. 
AGEs, coronary heart disease and diabetic heart failure
Elevated serum levels of  AGEs such as CML have been 
documented in type 2 diabetic patients with coronary 
heart disease[31]. AGEs have been detected in atheroma-
tous lesions in coronary arteries of  diabetic patients, sug-
gesting a role of  AGEs in the accelerated development 
of  atherosclerosis reported in diabetics[40]. Moreover, 
serum AGE levels have been shown to be a biomarker 
for the severity of  coronary artery atherosclerosis in type 
2 diabetic patients[27] independent from other well known 
risk factors such as hypertension, hyperlipidaemia and 
smoking. Higher serum AGE levels were detected in 
type 2 diabetic patients with obstructive coronary artery 
disease in comparison to diabetics with non-obstructive 
coronary disease and AGE serum levels were found to 
correlate with the degree of  the coronary atherosclerosis 
in those with obstructive coronary disease[41]. AGE levels 
have also been reported to influence the success rate of  
coronary artery revascularization in patients with diabe-
tes. Elevated serum AGE levels in patients undergoing 
percutaneous coronary intervention has been shown to 
be an independent risk factor for restenosis in diabetic 
patients[42]. Following cardiac surgery, serum AGE levels 
also inversely correlate with left ventricular ejection frac-
tion and are associated with prolonged ventilation time 
and prolonged stays on the Intensive Care Unit[43,44]. 
Other studies have demonstrated that elevated serum 
AGE levels have been shown to predict mortality due 
to coronary heart disease in female patients with type 2 
diabetes followed up for 18 years[31]. Similarly, increased 
serum AGE levels in type 1 diabetes have been shown to 
correlate with incident fatal as well as nonfatal cardiovas-
cular events independent from other known cardiovas-
cular risk factors such as age, body mass index, smoking, 
hypertension and hyperlipidaemia[45]. 
The risk of  development of  cardiovascular disease is 
increased by a factor of  2-4 fold in diabetic patients[46]. 
DM is considered to be an independent risk factor for 
incident heart failure (HF)[47-49]. In the Framingham study 
(between the ages 45-74), the risk of  developing HF was 
higher in diabetic males (2.4:1) and diabetic females (5:1) 
independent of  age, obesity, hypertension, hyperlipidae-
mia and coronary artery disease[50].
Elevated serum levels of  AGEs in patients with dia-
betes accelerate the development and progression of  
heart failure both indirectly through their vascular effects 
(coronary dysfunction, atherosclerosis and thrombosis) 
and directly through direct actions on the myocardium. 
In the former, AGEs binding to their cell surface recep-
tor (RAGE) on endothelial cells, smooth muscle cells 
and monocytes thereby inducing a wide range of  signal-
ing pathways that trigger inflammation, atherogenesis 
and vasoconstriction leading to coronary dysfunction, 
atherosclerosis and thrombosis[14]. On the other hand, 
AGEs have been reported to have a direct effect on 
the myocardium independent of  effects on the vascular 
tree, mediated in part via cross linking of  extracellular 
cardiac proteins and through actions mediated by AGE 
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Figure 1  Maillard reaction. Schematic illustration of the Maillard process that starts by a non-enzymatic reaction of a protein lysine residue (as an example of the 
most common residues that get glycated) and glucose with consequent loss of a water molecule. This is a reversible reaction that takes place over a few hours lead-
ing to the formation of an unstable compound (Schiff base). The latter undergoes molecular rearrangements over a period of days yielding a more stable compound 
known as (the Amadori product). Over months/years, the Amadori product turns to a very stable compound known as advanced glycation end product (AGE) through 
a series of reactions such as oxidation. Therefore AGE molecules acquire more negative charges. AGEs are irreversible once they are formed. The Maillard reaction 
leads to denaturation and browning of the modified proteins.
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receptors expressed on the myocardium[5,6,51]. AGEs have 
been implicated in the development of  both systolic and 
diastolic cardiac dysfunction in diabetics which may ex-
plain the increased prevalence of  heart failure in diabetic 
patients[14,52]. It was shown by Steine et al[53] that serum 
AGE levels and duration of  diabetes can predict systolic 
strain (as evaluated by doppler tissue imaging) in patients 
of  type 1 diabetes. Moreover, Kilhovd et al[31] showed 
that parameters of  left ventricular diastolic dysfunction, 
e.g., delayed isovolumetric relaxation time and reduced 
LV end-diastolic diameter correlate with elevated plasma 
AGE levels in type 2 diabetic patients. Similarly, Willem-
sen et al[54] showed that increased tissue levels of  AGEs (as 
detected by increased skin autofluorescence) in diabetic 
heart failure patients are independently associated with 
diastolic dysfunction and consequently reduced exercise 
capacity in those patients in comparison to non-diabetic 
heart failure patients.
Serum AGE levels have been demonstrated as inde-
pendent predictors of  both the severity and prognosis 
in heart failure patients[14,55]. Plasma pentosidine levels, 
one of  the crosslinking AGEs, has been shown to be an 
independent predictor of  both re-hospitalization and 
mortality in heart failure patients independent from oth-
er known risk factors such as brain natriuretic peptide 
(BNP), age, renal function and New York Heart Associ-
ation (NYHA) functional class[55]. Similarly, plasma levels 
of  N-CML, one of  the most prevalent antigenic AGEs 
in sera of  diabetic patients, have been shown to correlate 
with NYHA functional class and predict outcomes in 
patients with systolic heart failure[14].  
Another study conducted by Neeper et al[56] showed 
that serum levels of  soluble RAGE (sRAGE) are markers 
of  the development and the progression of  heart failure 
in diabetic and non-diabetic patients. The term sRAGE 
includes both cleaved RAGE (cRAGE) and endoge-
nously secreted RAGE (esRAGE). The former is cleaved 
RAGE from cell surface by action of  metalloproteinases 
that are increased in HF. This form lacks the V-domain 
and is therefore unable to neutralize AGEs. The latter is 
an endogenously secreted RAGE that helps to neutralize 
serum AGEs. Both higher serum levels of  cRAGE and 
lower serum levels of  esRAGE correlate with the severity 
of  cardiac dysfunction, severity of  symptoms and clinical 
outcomes in patients with heart failure[56]. Similar findings 
have been recorded in a number of  other HF studies. For 
instance, Koyama et al[57] have shown that serum levels of  
sRAGE correlate with NYHA functional class and that 
they are particularly higher in HF patients with preserved 
EF suggesting that they have a role in diastolic dysfunc-
tion. Furthermore, Koyama et al[57] reported that sRAGE 
levels are independent prognostic factors in HF[57]. Simi-
larly, Raposeiras-Roubín et al[58] also demonstrated that 
sRAGE is a highly sensitive and specific marker of  prog-
nosis of  HF patients.
Other studies have yielded conflicting observations 
about the role of  AGEs in the development of  heart 
failure whether directly or indirectly. For instance, in 
another study, the authors demonstrated that increased 
serum sRAGE levels are associated with increased sever-
ity of  HF particularly in patients with an ischemic cause 
of  heart failure although this correlation was shown to 
be independent of  AGE serum levels[59]. Similarly, in 
the study of  Campbell et al[60], left ventricular biopsies 
were taken from pre-diabetic, type 2 diabetic and control 
subjects undergoing coronary heart bypass surgery to 
assess myocardial fibrosis and myocardial expression of  
the AGE N-CML and the RAGE. All the patients had 
similar degrees of  coronary disease with no previous 
history of  myocardial infarction or heart failure although 
diabetic patients exhibited diastolic dysfunction on echo-
cardiography. The study demonstrated no significant dif-
ferences in either myocardial AGE or RAGE expression 
between patient groups or the control group suggesting 
that myocardial AGE/RAGE expression was not an 
important factor in diastolic dysfunction development in 
diabetes. In a similar study in which endomyocardial bi-
opsies of  failing hearts of  diabetic patients were studied, 
no increase in myocardial fibrosis or myocardial CML 
expression was observed in cases with preserved left 
ventricular ejection fraction although both myocardial 
fibrosis and CML expression were elevated in cases with 
significant systolic dysfunction[60].
AGEs and other forms of macrovascular diseases
Serum levels of  AGEs were also shown to correlate with 
the presence of  other forms of  macrovascular pathol-
ogy as carotid stenosis and peripheral artery occlusive 
disease. Serum levels of  the esRAGE that can neutralize 
circulating AGEs were found to be inversely propor-
tionate to carotid artery intima-media thickness in type 
1 diabetic patients[61]. The same was reported in type 2 
diabetic patients as well as non-diabetic cases[62]. Higher 
expression of  the RAGE was detected in carotid artery 
plaques and was shown to be associated with enhanced 
inflammatory reactions[63].
Type 2 diabetic patients with peripheral artery dis-
ease exhibited higher levels of  serum AGEs vs the non-
diabetic subjects[39]. A tight link has been shown between 
AGE plasma levels and pulse pressure in type 1 diabetic 
patients as was reported in the EURODIAB Prospective 
Complications Study[64].
AGEs and microangiopathy
Serum and tissue levels of  AGEs are predictors of  the 
development of  microvascular complications in diabetes. 
For example in type 1 diabetes control and complications 
trial, increased AGE levels in skin biopsies predict the 
development of  diabetic microvascular complications, 
e.g., retinopathy and nephropathy[13,65]. AGE/RAGE 
interaction has been suggested as a possible mechanism 
coupling microangiopathy with diabetic nephropathy, 
retinopathy and neuropathy[43].
Diabetic nephropathy: Correlation between the levels 
of  skin collagen AGEs particularly CML and the devel-
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opment and worsening of  microvascular complications 
including nephropathy in type 1 diabetic patients was 
initially reported by Genuth et al[65]. Similarly, in type 2 
diabetes skin AGEs (skin autofluorescence) were shown 
to be potent independent predictors of  evolution of  mi-
crovascular complications including nephropathy[66]. In 
diabetes, the kidney is an important site for AGE accu-
mulation but also contributes to the increased levels of  
AGEs in the serum of  diabetic patients since the kidney 
is the main site for AGE clearance[67]. Diabetic animal 
models exhibit higher levels of  AGE deposition in their 
kidneys[68] which has been linked to renal structural alter-
ations reported in diabetic nephropathy such as glomer-
ular basement membrane thickening, glomerulosclerosis, 
mesangial expansion and tubulointerstitial fibrosis. Simi-
lar histological findings have also been also documented 
in murine models injected with AGE-albumin[69].
Diabetic retinopathy: Accumulation of  AGEs espe-
cially CML in retinal blood vessels of  type 2 diabetic 
patients has been reported. It has been also documented 
that the levels of  AGEs correlated with the severity of  
the retinopathy[70,71]. Infusion of  AGE-albumin in non-
diabetic animals has shown that AGEs localize both 
inside and around the pericytes co-localizing with the 
AGE receptor causing thickening of  the basement mem-
brane and destruction of  the blood retinal barrier[72,73]. In 
vitro exposure of  retinal cells to AGEs induced upregula-
tion of  vascular endothelial growth factor (VEGF) that 
may contribute to retinal neovascularisation reported in 
diabetic retinopathy[74].
Diabetic neuropathy: Both peripheral and autonomic 
neuropathies have been shown to correlate with AGE 
levels even before neuropathy becomes clinically evi-
dent[75]. Skin autofluorescence reflecting AGE bound 
collagen levels has been reported to have a tight link with 
the degree of  diabetic neuropathic foot ulceration[76]. 
AGEs have been shown to accumulate in peripheral 
nerves of  diabetic patients and they were shown to co-
localize with RAGE receptor in endoneurial, perineurial 
and epineurial blood vessels[77].
MECHANISMS OF ACTIONS OF AGES
AGEs mediate their tissue effects through three main 
mechanisms: (1) Cross linking extracellular (matrix) pro-
teins thereby affecting tissue mechanical properties[51]; 
(2) Cross linking intracellular proteins thus altering their 
physiological functions[5,6]; and (3) Binding to their cell 
surface receptor RAGE to inducing multiple intracellu-
lar signalling cascades[56]. In the following sections these 
mechanisms will be discussed.
Crosslinking tissue proteins
Cross linking extracellular matrix proteins: AGE for-
mation is a process of  chronicity usually affecting long-
lived proteins. Extracellular matrix proteins especially 
collagen type Ⅳ that is involved in basement membrane 
structure, are more prone to advanced glycation due 
to their long turnover[20,78]. Advanced glycation and 
crosslinking of  other extracellular matrix proteins, e.g., 
collagen Ⅰ and elastin render them stiffer and less sus-
ceptible to proteolytic digestion[51] (Figure 2). This may 
contribute to the observed increase in vascular stiffness 
reported in diabetes and old age[20,51,79]. In addition, cross 
linking myocardial collagen with AGEs has been sug-
gested to cause myocardial stiffness and diastolic dys-
function in diabetic patients[51,80].
AGEs alter the structure of  low density lipoproteins 
(LDL) through glycation therefore preventing their clear-
ance from the circulation via the normal elimination 
route, i.e., uptake by the endothelial cells. Instead they are 
uptaken by the blood monocytes leading to foam cells 
that contribute to the pathogenesis of  atherosclerosis[81,82].
Cross linking intracellular proteins: AGEs have been 
shown to be implicated in crosslinking of  intracellular pro-
teins and hence altering their physiological properties and 
functions. For instance AGEs were shown to cross link 
the domains of  both the Ryanodine receptor[5] and SER-
CA2a[6] in cardiomyocytes leading to alterations in calcium 
homeostasis reported in diabetic cardiomyopathy[83,84].
RAGE dependant effects of AGEs
RAGE receptor: RAGE belongs to the immunoglobu-
lin superfamily of  receptors[56]. It has been reported that 
RAGE gene is located on chromosome 6 in humans 
between genes coding for class Ⅱ and class Ⅲ major 
histocompatibility complexes[85]. The RAGE promoter 
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Figure 2  Effects of advanced glycation end products on extracellular 
matrix proteins. In extracellular matrix, advanced glycation end products 
(AGEs) form on different molecules as collagen, laminin and elastin. This alters 
the physiological properties of the matrix and increases its stiffness. AGEs 
upregulate transforming growth factor (TGF)-b that increases the production of 
extracellular matrix components by binding to its receptor.
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has been shown to possess nuclear factor kappa B (NF-
κB) binding sites, hence linking RAGE expression to the 
inflammatory cascade[86]. 
RAGE is a multiligand receptor with advanced glyca-
tion end products being identified as its first known li-
gands. Hereafter, multiple other RAGE ligands have been 
revealed including; high mobility group protein box-1[21], 
some members of  the S100 protein family[87] amyloid 
b[88,89] and fibrillar protein aggregates[90,91]. Therefore, 
RAGE has an important role in the pathogenesis of  the 
diseases induced by such ligands, e.g., inflammation, tu-
mours, neurodegeneration and amyloidoses[21,88,92,93].
RAGE structure: Full length RAGE comprises three 
domains, an extracellular domain of  332-amino acids ar-
ranged as a single “V”-type immunoglobulin-like (variable) 
domain with subsequent two “C”-type (constant) do-
mains[89,94]. Modern biochemical techniques have revealed 
evidence suggesting that both the V and C1 domains of  
RAGE function together as an incorporated single struc-
tural unit for the binding of  some ligands. In contrast, C2 
RAGE domain is suggested to function completely inde-
pendent from the VC1 complex while remaining attached 
to it through a flexible hinge (Figure 3). It has been 
deduced from experimental work that different RAGE 
ligands interact with one or more of  its domains[19].
RAGE has a single transmembrane domain and a 
highly charged cytosolic tail formed of  43 amino acids 
(Figure 3). The cytosolic tail is vital for RAGE ligands to 
activate intracellular signalling cascades. RAGE isoforms 
in which the cytosolic tail was absent, bind AGEs but 
fail to elicit intracellular signaling on ligand binding[95]. It 
has recently been shown that for some RAGE actions, 
its tail binds directly to a cytoplasmic molecule known as 
the mammalian diaphanous-1 which is essential for elic-
iting phosphorylation/activation steps needed for initia-
tion of  the signalling cascade[96]. 
Despite the wide variation in their chemical structure, 
AGEs bind to the V domain of  the RAGE receptor[94]. 
The fact that RAGE recognizes a class of  biochemi-
cally heterogeneous ligands such as AGEs categorizes 
RAGE as one of  the pattern recognition receptors[97-99] 
that identifies common features or patterns rather than 
a specific ligand. Though AGEs exhibit diverse chemi-
cal structure, however, they have some common general 
characteristics. First, all AGE modified proteins demon-
strate a net negative charge that accumulates during their 
formation by glycation and oxidation[100,101]. The second 
main feature is that modifications of  proteins by AGEs 
lead to creation of  multiple covalent cross-links resulting 
in higher molecular mass molecules (multimers). This 
ligand geometry is thought to be important for RAGE 
activation[100].
Recent molecular structure revealing technologies 
including X-ray crystallographic, NMR together with 
conventional biochemical data have illustrated that the 
unusual ability of  the RAGE receptor to bind different 
AGEs lies in its extracellular portion (VC1 ectodomain) 
where it has been suggested that the ligand binding is 
triggered mainly by electrostatic interactions between the 
positively charged surface of  this subunit and negatively 
charged ligands (Figure 3)[102]. The V domain has been 
shown by NMR to exhibit three distinct areas for medi-
ating AGE-V domain interactions. Such areas are situ-
ated in the positively charged regions of  the V domain. 
The first interaction surface includes strand C and loop 
CC’, the second interaction surface comprises strand C’, 
strand F and loop FG, and the third interaction one con-
sists of  strand A’ and loop EF[101]. 
The second main point to be considered here is that 
studies based on using a fluorescence-labelled receptor 
demonstrated that RAGE does not float as one molecule 
in the plasma membrane but instead multiple RAGE 
receptors aggregate to form receptor assemblies[19,101]. 
Therefore, RAGE exists in constitutive multimers that 
usually includes four molecules or more within the 
plasma membrane[101,103]. RAGE multimers are thought 
to display a parallel orientation with VC1 subunits exhib-
iting side to side contacts (Figure 3) as revealed in pro-
tein crystals. Therefore it has been speculated that the 
general multimeric structure adopted by AGE modified 
proteins together with numerous AGE-modified side 
chains are essential requirements for preserving the re-
ceptor assemblies’ stability needed for activation of  the 
receptor[100] probably in a similar way to that previously 
described for the receptor tyrosine kinases where the in-
tracellular domains of  the receptor that possess intrinsic 
kinase activity must come very close together in a partic-
ular orientation that facilitates cross-phosphorylation of  
the domains and hence commencement of  the signalling 
cascade[104].
RAGE isoforms: Despite the presence of  a single gene 
coding for RAGE, there are several splice variants of  this 
gene with three main RAGE isoforms having been iden-
tified: full length RAGE, dominant-negative RAGE (DN-
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Figure 3  Receptor for advanced glycation end product (i.e., colon) recep-
tor structure and its functional implication in binding different advanced 
glycation end products. A diagrammatic illustration of the structure of the re-
ceptor for advanced glycation end product (RAGE) showing that it is composed 
of an extracelluar portion, a transmembrane portion and an intracytoplasmic tail. 
The extracelluar portion comprises three domain V, C1 and C2. The first two 
are believed to work together as a single functional complex (VC1) whereas the 
C2 domain remains attached to the VC1 complex but works independently from 
it. The diagram also illustrates how multiple RAGE receptors polymerise within 
the cell membrane  to facilitate high affinity binding of the positively charged V 
domain with the negatively charged advanced glycation end products (AGEs) 
independent of their chemical structure. That is why RAGE is considered one of 
the pattern recognition receptors.
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RAGE) and endogenous soluble RAGE (es-RAGE)[105]. 
Full length RAGE is composed of  the whole three 
domains; extracellular, trans-membrane and intracellular 
domains. DN-RAGE has extracellular and transmem-
brane domains, but no cytosolic tail. Endogenous soluble 
RAGE possesses the extracellular domain only so it is 
found free in the circulation. The only RAGE isoform 
that is capable of  eliciting intracellular signalling upon in-
teracting with its ligands is the full length RAGE as this is 
induced through its cytosolic tail. However, the other two 
isoforms; DN-RAGE and esRAGE help in clearance and 
neutralisation of  circulating AGEs by competing with full 
length RAGE in binding them[56,105].
RAGE tissue distribution: RAGE expression has been 
detected in a number of  cells including endothelial 
cells, smooth muscle cells, monocytes/macrophages, 
T lymphocytes, cardiomyocytes, glomerular podocytes, 
dendritic cells, neurons of  the central and peripheral 
nervous systems and transformed cells[106]. Generally, 
there is a low expression of  RAGE in tissues. However, 
it becomes up-regulated in an environment rich with its 
ligands as in the case of  diabetes or aging. RAGE ex-
pression was higher in endothelial cells, monocytes and 
smooth muscles in diabetic vascular tissue[107]. 
INTRACELLULAR EFFECTS OF AGE-RAGE 
BINDING ON CARDIOVASCULAR SYSTEM
RAGE activation by high serum and tissue levels of  
AGEs induces multiple intracellular signalling pathways 
(Figure 4) that have been implicated in pathogenesis of  
serious diabetic complications such as enhanced athero-
sclerosis, cardiovascular disease, nephropathy and chron-
ic inflammation[9,10,108-110]. It has been documented that 
circulating AGEs bind with endothelial RAGE resulting 
in endothelial dysfunction via activation of  a number of  
signaling pathways, e.g., activation of  nicotinamide ad-
enine dinucleotide phosphate oxidase that enhances the 
production of  reactive oxygen species (ROS)[108]. ROS 
have been shown to play a pivotal role in causing major 
cardiovascular damage in diabetes through modifying the 
structure of  cellular proteins, lipids and nucleic acids and 
therefore altering their physiological roles[111]. 
In addition, it has been reported as well that AGE-
RAGE engagement increases phosphorylation of  p21ras, 
the mitogen-activated protein kinases, extracellular signal-
regulated kinase 1/2 and p38, and activates GTPases 
Cdc42 and Rac, ultimately inducing activation and trans-
location of  NF-κB from cytoplasm to the nucleus where 
it starts transcribing its target set of  genes[112]. The latter 
include, intercellular adhesion molecule-1, vascular cell 
adhesion molecule-1, VEGF, endothelin-1, tissue fac-
tor, E-selectin, thrombomodulin and proinflammatory 
cytokines, including interleukin (IL)-1α, IL-6 and tumor 
necrosis factor-α[113,114]. The above mentioned cytokines 
and adhesion molecules have central roles in both inflam-
mation and atherosclerosis[108,115]. 
ANTI-AGE THERAPIES 
Therapies that target AGEs can be classified into two 
main categories, the ones that prevent the formation of  
AGEs and others that breakdown the already formed 
AGEs. 
Prevention of AGEs formation
Aminoguanidine (AG), is a hydrazine compound that in-
hibits AGE formation via trapping of  carbonyl intermedi-
ates (early active glycation products) and hence preventing 
modification of  nucleophilic residues in proteins[116,117]. 
In a placebo-controlled, randomized trial involving type 
1 diabetes patients, the use of  aminoguanidine hindered 
reduction in glomerular filtration rate, reduced 24-h uri-
nary proteinuria and prevented the deterioration of  reti-
nopathy. However, it did not influence time-to-doubling 
of  serum creatinine[118]. Being an NOS inhibitor, which is 
an essential renovasodilator, this may offset some of  AG 
benefits as an AGE inhibitor[119].
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Figure 4  Intracellular effects of AGEs after AGE/RAGE binding. Diagram-
matic representation of AGE/RAGE interaction on the surface of an endothelial 
cell leads to transduction of a signalling cascade; activates nicotinamide ade-
nine dinucleotide phosphate oxidase and enhances ROS production and phos-
phorylate p21 RAS and MAPKs. Moreover, the AGE/RAGE interaction induces 
signalling through activation of p38 MAPK. A main step in AGE/RAGE signalling 
is activation of NF-κB and its translocation to the nucleus, where it enhances 
transcription of target genes as endothelin-1, ICAM-1, E-selectin and tissue 
factor. Hence, AGE/RAGE binding triggers an inflammatory cascade. AGE may 
decrease NO availability by reducing eNOS activity and by inactivating NO. 
AGE: Advanced glycation end-product; RAGE: Receptor for advanced glycation 
end products; ROS: Reactive oxygen species; MAPKs: Mitogen-activated pro-
tein kinases; ERK1/2: Extracellular signal-regulated kinase 1/2; NF-κB: Nuclear 
factor kappa B; ICAM-1: Intercellular adhesion molecule-1; VCAM-1: Vascular 
cell adhesion molecule-1; VEGF: Vascular endothelial growth factor; IL-1α: 
Interleukin-1α; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-α; eNOS: En-
dothelial nitric oxide synthase; NO: Nitric oxide.
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Pyridoxamine, (form of  vitamin B6 that naturally ex-
ists) and benfotiamine (a lipid-soluble derivative of  thia-
mine), are known to inhibit AGE formation. In phase 2 
trials using pyridoxamine in diabetic patients suffering 
from obvious diabetic nephropathy, a significant decline 
in the serum levels of  creatinine from baseline was ob-
served although this was not accompanied by a corre-
sponding change in urinary albumin excretion[120]. Using 
benfotiamine in type 2 diabetic patients prevented both 
macro- and microvascular endothelial dysfunction and 
oxidative stress induced by an AGE rich meal[121]. More-
over, the combined use of  benfotiamine and alpha-lipoic 
acid normalized elevated AGE levels and blocked the 
enhancement hexosamine-modified protein formation in 
monocytes in type 1 diabetic patients[122].
AGE degradation (AGE cross link breaker, ALT-711)
Cross link breakers such as ALT-711 contain a thiazo-
lium structure that is capable of  breaking α-carbonyl 
compounds by cleaving the carbon-carbon bond be-
tween carbonyls. In vitro, incubation of  AGE crosslinked 
collagen with ALT-711 promotes collagen digestibility by 
metalloproteinases (MMP), a phenomenon used as a key 
sign of  an effective cross link-breaker effect[123]. 
ALT-711 has been used in a number of  small clini-
cal studies to investigate the effects of  targeting AGE 
on cardiovascular complications. A phase Ⅱ clinical trial 
demonstrated that ALT-711 (210 mg/d, 8 wk) reduced 
the arterial pulse pressure and improved the compliance 
of  large arteries in older patients (> 50 years) who ex-
hibited age-dependent stiffening of  their large arteries 
secondary to isolated systolic hypertension[124].
Two more phase 2b clinical trial trials currently being 
undertaken to assess the safety as well as the efficacy of  
ALT-711 use in the treatment of  isolated systolic hy-
pertension with or without left ventricular hypertrophy 
(LVH) in elderly patients (> 50 years), termed systolic 
and pulse pressure hemodynamic improvement by re-
storing elasticity (SAPPHIRE) and systolic hypertension 
interaction with left ventricular remodeling (SILVER). 
SAPPHIRE is designed to use multiple doses (four) of  
ALT-711 over a period of  6 mo in patients with systolic 
hypertension without LVH whilst the control group 
will be treated with placebo. The SILVER study is being 
conducted on patients with systolic hypertension and 
LVH, including both diabetics and non-diabetics treated 
with a single dose of  ALT-711 and a placebo group for 
6 mo. The primary endpoints of  both studies are altera-
tions in both systolic blood pressure and pulse pressure. 
Secondary endpoints involve extra measurements of  
arterial blood pressure and modifications in definite uro-
logical parameters. The results of  both trials are still not 
yet available[125].
In addition, two small and open label clinical trials 
suggested an important role of  AGEs in the develop-
ment of  cardiac dysfunction and HF. In both trials HF 
patients were treated with an AGE cross-link breaker Al-
agebrium (ALT-711). In the Distensibility Improvement 
and Remodeling in Diastolic Heart Failure (DIAMOND) 
trial, 23 patients with stable diastolic HF received 
ALT-711 for 16 wk after which patients were assessed 
by magnetic resonance imaging and tissue doppler which 
revealed both a reduction of  left ventricular mass and 
an improvement of  left ventricular diastolic function[126]. 
The Patients with Impaired Ejection Fraction and Dia-
stolic Dysfunction: Efficacy and Safety Trial of  Alage-
brium trial was conducted on 22 patients suffering from 
systolic HF and diastolic dysfunction who were treated 
by ALT-711 (35-420 mg). The results of  this trial were in 
line with those of  the DIAMOND trial. Doppler assess-
ment showed improvement in isovolumetric relaxation 
time and consequently reduction in the left atrial pres-
sure. Furthermore, reduced left ventricular mass and left 
ventricular end-diastolic volume was also reported in 
some patients[127]. 
However, a more recent clinical trial BENEFICIAL, 
a prospective, randomized, double-blind, phase Ⅱ, pla-
cebo controlled trial on the effects of  the AGE-breaker 
alagebrium on exercise capacity and diastolic function in 
102 patients with systolic HF did not support the find-
ings of  the earlier trials. In BENEFICIAL study, patients 
were assessed after receiving 200 mg alagebrium twice 
daily or placebo treatment for a period of  36 wk. No im-
provement was reported in exercise capacity or systolic 
function of  those patients. In addition, no significant 
change was detectable in a number of  other parameters 
including diastolic dysfunction, NYHA functional class, 
NT pro-BNP levels and AGE levels (skin autofluores-
cence). However, the authors highlighted some impor-
tant points that may explain their findings. Firstly, inclu-
sion into this study did not mandate the presence of  
diastolic dysfunction as an entry criterion into the trial, 
and it is this sub group with diastolic dysfunction that 
may have shown a better response to alagebrium treat-
ment. Secondly, tissue AGE levels were relatively low in 
the patient cohort, especially since only (18%) of  the pa-
tients included into this study were diabetic. Finally, the 
duration of  treatment might be to short for alagebrium 
to produce a therapeutic effect[128]. 
Anti-RAGE receptor therapies
Recently, therapies targeting the RAGE receptor, e.g., 
sRAGE have been used in experimental studies and 
proved to be effective in reducing atherosclerosis in dia-
betic mice[129,130] as well as microvascular complications 
of  diabetes as diabetic retinopathy[131], nephropathy[132] 
and neuropathy[98]. The use of  the latter in the clinical 
setting has not yet been approved. 
CONCLUSION
Cardiovascular diseases are one of  the leading causes of  
morbidity and mortality in the western world particularly 
amongst patients with diabetes. AGEs accumulate rap-
idly in the hyperglycaemic milieu of  diabetes and have 
an important role in the development of  the macro and 
97 April 26, 2012|Volume 4|Issue 4|WJC|www.wjgnet.com
Hegab Z et al . Role of AGE in cardiovascular disease
microvascular complications of  diabetes. 
Several clinical and experimental studies support the 
view that AGEs might have a significant role in patho-
genesis of  heart failure by contributing to its develop-
ment and progression either via indirect mechanisms 
mediated through enhancing coronary artery disease or 
directly by inducing myocardial damage independent of  
vascular effects. AGEs adverse effects on cellular and 
tissue function arise from their potential to cross link 
intracellular and extracellular proteins thus altering their 
function and through binding to their cell surface recep-
tor RAGE activating multiple signalling cascades in many 
different cells within the cardiovascular system. Prelimi-
nary data suggests that targeting AGEs therapeutically 
may represent a novel treatment strategy in the manage-
ment of  DM and its cardiovascular complications.
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